However, when a lysine methyltransferase inhibitor (siKmt2c) was applied, the symptoms of inflammation and hyperplasia were alleviated, indicating that the inhibition of KMT2C can disrupt the immune cycle in immune diseases such as psoriasis [45]. This evidence concerns the gene KMT2C and immune system disorder.